Here’s a question almost nobody is asking: how do you get to the Times Square Olive Garden? Well, these beautiful weirdos are ...

Endless breadsticks, now at your fingertips!

The Artemis Watch 2.0, made by CircuitMess, is a $129 programmable smartwatch designed less as a gadget you wear and more as something you can digitally rebuild into your own creation.

Kanen bought 1,573,950 Compass shares; estimated trade size $14.36 million based on quarterly average price. Quarter-end Compass position value rose by $29.11 million, reflecting both trading and ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...

U.S. antitrust enforcers should consider blocking a bid by Compass, the nation’s largest residential real estate broker, to acquire rival Anywhere Real Estate, amid a housing shortage, two Democratic ...

Compass, the nation’s largest residential real-estate brokerage, has a pitch for home buyers: Sign with us, and you’ll see homes nobody else can. The company maintains a growing inventory of “Private ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A psychedelic medicine for hard-to-treat depression ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...